Lixoft Overview

Status Acquired/​Merged
Employees 11
Latest Deal Type M&A
Latest Deal Amount $16.5M
Latest Deal Amount

Lixoft General Information


Developer of a modeling and simulation platform designed to reduce the cost and increase the success rate of new drug development. The company's platform deals in model-based drug development and advances to the modeling and simulation community in user-friendly tools designed to break the preclinical/clinical/vigilance divide for modeling and simulation, enabling drug developers to share information and synthesize them in studies.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Other Healthcare Technology Systems
Discovery Tools (Healthcare)
Parent Company
Primary Office
  • 8 rue de la Renaissance
  • Batiment D
  • 92160 Antony
  • France
+33 09 00 00 00 00
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lixoft Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Apr-2020 $16.5M 000.00 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2010 Completed Startup

Lixoft Executive Team (2)

Name Title Board Seat Contact Info
Jonathan Chauvin Chief Executive Officer
Jérôme Kalifa Ph.D Co-Founder & Chairman

Lixoft Board Members (1)

Name Representing Role Since
Jérôme Kalifa Ph.D Lixoft Co-Founder & Chairman 000 0000

Lixoft Former Investors (1)

To view Lixoft‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
IncubAlliance Accelerator/Incubator Minority 000 0000 000000 0

Ready to get started?

Request a free trial